Cargando…

BACE1 controls synaptic function through modulating release of synaptic vesicles

BACE1 initiates production of β-amyloid peptides (Aβ), which is associated with cognitive dysfunction in Alzheimer’s disease (AD) due to abnormal oligomerization and aggregation. While BACE1 inhibitors show strong reduction in Aβ deposition, they fail to improve cognitive function in patients, large...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Brati, Singh, Neeraj, Yao, Annie Y., Zhou, John, He, Wanxia, Hu, Xiangyou, Yan, Riqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760050/
https://www.ncbi.nlm.nih.gov/pubmed/34158621
http://dx.doi.org/10.1038/s41380-021-01166-2
_version_ 1784633236499988480
author Das, Brati
Singh, Neeraj
Yao, Annie Y.
Zhou, John
He, Wanxia
Hu, Xiangyou
Yan, Riqiang
author_facet Das, Brati
Singh, Neeraj
Yao, Annie Y.
Zhou, John
He, Wanxia
Hu, Xiangyou
Yan, Riqiang
author_sort Das, Brati
collection PubMed
description BACE1 initiates production of β-amyloid peptides (Aβ), which is associated with cognitive dysfunction in Alzheimer’s disease (AD) due to abnormal oligomerization and aggregation. While BACE1 inhibitors show strong reduction in Aβ deposition, they fail to improve cognitive function in patients, largely due to its role in synaptic function. We show that BACE1 is required for optimal release of synaptic vesicles. BACE1 deficiency or inhibition decreases synaptic vesicle docking in the synaptic active zones. Consistently, BACE1-null mice or mice treated with clinically tested BACE1 inhibitors Verubecestat and Lanabecestat exhibit severe reduction in hippocampal LTP and learning behaviors. To counterbalance this synaptic deficit, we discovered that BACE1-null mice treated with positive allosteric modulators (PAMs) of metabotropic glutamate receptor 1 (mGluR1), whose levels were reduced in BACE1-null mice and significantly improved long-term potentiation and cognitive behaviors. Similarly, mice treated with mGluR1 PAM showed significantly mitigated synaptic deficits caused by BACE1 inhibitors. Together, our data suggest that a therapy combining BACE1 inhibitors for reducing amyloid deposition and an mGluR1 PAM for counteracting BACE1-mediated synaptic deficits appears to be an effective approach for treating AD patients.
format Online
Article
Text
id pubmed-8760050
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87600502022-01-26 BACE1 controls synaptic function through modulating release of synaptic vesicles Das, Brati Singh, Neeraj Yao, Annie Y. Zhou, John He, Wanxia Hu, Xiangyou Yan, Riqiang Mol Psychiatry Article BACE1 initiates production of β-amyloid peptides (Aβ), which is associated with cognitive dysfunction in Alzheimer’s disease (AD) due to abnormal oligomerization and aggregation. While BACE1 inhibitors show strong reduction in Aβ deposition, they fail to improve cognitive function in patients, largely due to its role in synaptic function. We show that BACE1 is required for optimal release of synaptic vesicles. BACE1 deficiency or inhibition decreases synaptic vesicle docking in the synaptic active zones. Consistently, BACE1-null mice or mice treated with clinically tested BACE1 inhibitors Verubecestat and Lanabecestat exhibit severe reduction in hippocampal LTP and learning behaviors. To counterbalance this synaptic deficit, we discovered that BACE1-null mice treated with positive allosteric modulators (PAMs) of metabotropic glutamate receptor 1 (mGluR1), whose levels were reduced in BACE1-null mice and significantly improved long-term potentiation and cognitive behaviors. Similarly, mice treated with mGluR1 PAM showed significantly mitigated synaptic deficits caused by BACE1 inhibitors. Together, our data suggest that a therapy combining BACE1 inhibitors for reducing amyloid deposition and an mGluR1 PAM for counteracting BACE1-mediated synaptic deficits appears to be an effective approach for treating AD patients. Nature Publishing Group UK 2021-06-22 2021 /pmc/articles/PMC8760050/ /pubmed/34158621 http://dx.doi.org/10.1038/s41380-021-01166-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Das, Brati
Singh, Neeraj
Yao, Annie Y.
Zhou, John
He, Wanxia
Hu, Xiangyou
Yan, Riqiang
BACE1 controls synaptic function through modulating release of synaptic vesicles
title BACE1 controls synaptic function through modulating release of synaptic vesicles
title_full BACE1 controls synaptic function through modulating release of synaptic vesicles
title_fullStr BACE1 controls synaptic function through modulating release of synaptic vesicles
title_full_unstemmed BACE1 controls synaptic function through modulating release of synaptic vesicles
title_short BACE1 controls synaptic function through modulating release of synaptic vesicles
title_sort bace1 controls synaptic function through modulating release of synaptic vesicles
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760050/
https://www.ncbi.nlm.nih.gov/pubmed/34158621
http://dx.doi.org/10.1038/s41380-021-01166-2
work_keys_str_mv AT dasbrati bace1controlssynapticfunctionthroughmodulatingreleaseofsynapticvesicles
AT singhneeraj bace1controlssynapticfunctionthroughmodulatingreleaseofsynapticvesicles
AT yaoanniey bace1controlssynapticfunctionthroughmodulatingreleaseofsynapticvesicles
AT zhoujohn bace1controlssynapticfunctionthroughmodulatingreleaseofsynapticvesicles
AT hewanxia bace1controlssynapticfunctionthroughmodulatingreleaseofsynapticvesicles
AT huxiangyou bace1controlssynapticfunctionthroughmodulatingreleaseofsynapticvesicles
AT yanriqiang bace1controlssynapticfunctionthroughmodulatingreleaseofsynapticvesicles